NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 230 filers reported holding NEKTAR THERAPEUTICS in Q3 2022. The put-call ratio across all filers is 0.14 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,761,732 | +4569.3% | 2,936,218 | +5347.5% | 0.00% | – |
| Q1 2023 | $37,730 | -62.3% | 53,900 | +73.1% | 0.00% | – |
| Q3 2022 | $100,000 | -79.8% | 31,144 | -15.0% | 0.00% | -100.0% |
| Q4 2021 | $495,000 | -67.5% | 36,643 | -58.7% | 0.00% | -85.7% |
| Q2 2021 | $1,523,000 | -16.5% | 88,751 | +5.0% | 0.01% | -46.2% |
| Q4 2019 | $1,825,000 | -78.0% | 84,520 | -65.8% | 0.01% | -66.7% |
| Q1 2019 | $8,312,000 | +36.2% | 247,434 | +33.3% | 0.04% | -37.1% |
| Q4 2018 | $6,101,000 | +687.2% | 185,608 | +2445.7% | 0.06% | +93.8% |
| Q1 2018 | $775,000 | +80.7% | 7,291 | -66.0% | 0.03% | +68.4% |
| Q2 2017 | $429,000 | -95.8% | 21,444 | -97.4% | 0.02% | -71.6% |
| Q4 2016 | $10,184,000 | -0.9% | 829,982 | +38.7% | 0.07% | -8.2% |
| Q3 2016 | $10,277,000 | +203.2% | 598,207 | +151.2% | 0.07% | +160.7% |
| Q2 2016 | $3,389,000 | -38.0% | 238,180 | -26.5% | 0.03% | -45.1% |
| Q4 2015 | $5,462,000 | +466.6% | 324,124 | +305.6% | 0.05% | +264.3% |
| Q3 2014 | $964,000 | – | 79,904 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |